ホームニュースプライマリ・ケア領域で役立つエビデンスNo.74：不定愁訴をきたす患者の癌リスクとコロナワクチン接種者におけるモヌルピラビルの効果【Podcast：にゃんごう＆いがさんのEBMerな夜】
ニュース
プライマリ・ケア領域で役立つエビデンス
No.74：不定愁訴をきたす患者の癌リスクとコロナワクチン接種者におけるモヌルピラビルの効果【Podcast：にゃんごう＆いがさんのEBMerな夜】
にゃんごう＆いがさんのEBMerな夜
第74回放送 2023/1/30
【にゃんごう：不定愁訴をきたす患者の癌リスク】
White B, Renzi C, Barclay M,
Lyratzopoulos G. Underlying cancer risk among patients with fatigue and other vague symptoms: a population-based cohort study in primary care.
Br J Gen Pract. 2023 Jan 26;73(727):e75-e87. doi: 10.3399/BJGP.2022.0371.
PMID: 36702593.
https://bjgp.org/content/73/727/e75.full
【いがさん：コロナワクチン接種者におけるCOVID-19に対するモヌルピラビルの効果】
Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, Dorward J, Lowe DM, Standing JF, Breuer J, Khoo S, Petrou S, Hood K, Nguyen-Van-Tam JS, Patel MG, Saville BR, Marion J, Ogburn E, Allen J, Rutter H, Francis N, Thomas NPB, Evans P, Dobson M, Madden TA, Holmes J, Harris V, Png ME, Lown M, van Hecke O, Detry MA, Saunders CT, Fitzgerald M, Berry NS, Mwandigha L, Galal U, Mort S, Jani BD, Hart ND, Ahmed H, Butler D, McKenna M, Chalk J, Lavallee L, Hadley E, Cureton L, Benysek M, Andersson M, Coates M, Barrett S, Bateman C, Davies JC, Raymundo-Wood I, Ustianowski A, Carson-Stevens A, Yu LM, Little P; PANORAMIC Trial Collaborative Group.
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
Lancet. 2023 Jan 28;401(10373):281-293. doi: 10.1016/S0140-6736(22)02597-1. Epub 2022 Dec 22.
PMID: 36566761; PMCID: PMC9779781.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02597-1/fulltext
リスナーアンケートにご協力下さい！！
https://goo.gl/forms/5AsPilK7QnB9VrmX2
第74回放送 2023/1/30
【にゃんごう：不定愁訴をきたす患者の癌リスク】
White B, Renzi C, Barclay M,
Lyratzopoulos G. Underlying cancer risk among patients with fatigue and other vague symptoms: a population-based cohort study in primary care.
Br J Gen Pract. 2023 Jan 26;73(727):e75-e87. doi: 10.3399/BJGP.2022.0371.
PMID: 36702593.
https://bjgp.org/content/73/727/e75.full
【いがさん：コロナワクチン接種者におけるCOVID-19に対するモヌルピラビルの効果】
Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, Dorward J, Lowe DM, Standing JF, Breuer J, Khoo S, Petrou S, Hood K, Nguyen-Van-Tam JS, Patel MG, Saville BR, Marion J, Ogburn E, Allen J, Rutter H, Francis N, Thomas NPB, Evans P, Dobson M, Madden TA, Holmes J, Harris V, Png ME, Lown M, van Hecke O, Detry MA, Saunders CT, Fitzgerald M, Berry NS, Mwandigha L, Galal U, Mort S, Jani BD, Hart ND, Ahmed H, Butler D, McKenna M, Chalk J, Lavallee L, Hadley E, Cureton L, Benysek M, Andersson M, Coates M, Barrett S, Bateman C, Davies JC, Raymundo-Wood I, Ustianowski A, Carson-Stevens A, Yu LM, Little P; PANORAMIC Trial Collaborative Group.
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
Lancet. 2023 Jan 28;401(10373):281-293. doi: 10.1016/S0140-6736(22)02597-1. Epub 2022 Dec 22.
PMID: 36566761; PMCID: PMC9779781.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02597-1/fulltext
リスナーアンケートにご協力下さい！！
https://goo.gl/forms/5AsPilK7QnB9VrmX2
最終更新：2023年01月31日 14時58分
